The GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTThe GLP Weekend25% off GLPs15% off automatically25% with any codeEnds Sunday 11:59 PM PTUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →Free gift on orders $300+ · choose GLP-3 RT 5MG, GHK-Cu 100MG, NAD+ 500MG or MOTs-C 10MGUse code WELCOME10 for 10% off your orderFREE FEDEX 2-DAY shipping on orders over $250!Military · Veterans · First Responders: Verify & Save →
Research Guide

KY-19382
Research Guide

A Research Use Only reference to KY-19382: identity data, what published studies examined, handling and storage for laboratories.

Research reference · Updated October 10, 2026 · How we check our guides

What is KY19382?

KY19382 (also written KY-19382) is 5,6-dichloroindirubin-3′-methoxime, a synthetic small molecule from Kang-Yell Choi's group at Yonsei University, Seoul. From 60 new indirubin derivatives, the group picked KY19382 because it blocked CXXC5, a negative regulator of Wnt signaling, from binding Dishevelled and also inhibited GSK-3β (Choi et al., 2019).

All published work is preclinical, and several papers disclose that the senior author leads a company licensed to develop it (Ryu et al., 2021). Disguised Alpha supplies it as a liquid research solution at 5MG/ML in a 30ML bottle (150MG total) for laboratory research use only. Nothing on this page is guidance for use in people.

KY19382 reference data

PropertyValue
NameKY19382
Also calledKY-19382, KY 19382, 5,6-dichloroindirubin-3′-methoxime
StructureIndirubin core with chlorine atoms at positions 5 and 6 and a methoxime group (C=N-OCH₃) at position 3′; no amino acids or peptide bonds
Compound classSynthetic indirubin derivative; small-molecule Wnt/β-catenin activator (CXXC5-Dishevelled blocker and GSK-3β inhibitor)
Molecular formulaC₁₇H₁₁Cl₂N₃O₂
Molecular weight360.2 g/mol
PubChem CID148959784
FormLiquid research solution, 5MG/ML in a 30ML bottle (150MG KY19382 per bottle)
TestingEvery order ships with certificate access for its lot, per the product page

Concentration, volume and storage are from the product page, which lists no formula or weight; those come from PubChem. PubChem holds three KY19382 records with this formula and weight (CIDs 148959784, 137473598 and 164575812) that differ only in the drawn geometry of the methoxime double bond. All three carry the same depositor-supplied synonym. This page cites CID 148959784, the record with the fullest synonym list.

See it beside the other compounds on this site in the peptide molecular weight reference table.

What the research covers

Published work on KY19382 falls into six areas, all preclinical. Eight of the 11 PubMed records that name it come from the developing laboratory; one wound study and two cancer-cell studies are from independent groups.

How KY19382 activates Wnt/β-catenin signaling

The developers screened for compounds that stop CXXC5, a negative feedback regulator, from binding the PDZ domain of Dishevelled (DVL). In cell-free assays KY19382 blocked that binding with an IC50 of 19 nM and inhibited GSK-3β with an IC50 of 10 nM.

In ATDC5 mouse chondrogenic cells it raised β-catenin and the Wnt targets Axin2 and Wisp1 without significantly changing 19 target genes of other pathways (Choi et al., 2019). In human dermal papilla cells, 5 µM raised β-catenin and alkaline phosphatase, a marker of hair-inducing activity, and β-catenin knockdown abolished that rise (Ryu et al., 2021). Models: cell-free assays, mouse and human cells.

KY19382 in hair follicle models

On shaved backs of 7-week-old male C57BL/6N mice in the resting (telogen) phase, 0.5 mM KY19382 applied daily for 28 days gave more regrown hair by weight, more hair follicles and thicker dermis, signs of growth (anagen) phase entry, than 100 mM minoxidil (n = 5 per group). It also raised wound-induced hair follicle neogenesis, counted as new alkaline phosphatase-positive follicles in 1 cm² wounds on 3-week-old mice (Ryu et al., 2021).

In diabetic mice (high-fat diet plus streptozotocin), 1.5 mM KY19382, but not minoxidil, restored anagen entry after plucking and follicle neogenesis in wounds, and 1 µM restored elongation of human follicles cultured in high glucose. The authors say full follicle regeneration in diabetic wounds still needs confirmation (Ryu et al., 2022). Adding the PKM2 activator TEPP-46 to 0.5 mM KY19382 raised regrowth and neogenesis beyond either alone (Ryu et al., 2022). Models: mice and cultured human follicles.

Skin wound closure models

In HaCaT keratinocytes and adult human dermal fibroblasts, 0.1 and 1 µM KY19382 raised migration, β-catenin, keratin 14, collagen I and α-SMA, and β-catenin knockdown blocked the effect. In male C3H mice with 1 cm full-thickness wounds, 0.05 or 0.1 mM applied daily sped wound closure and re-epithelialization, mostly complete by day 12 at 0.1 mM and ahead of an EGF comparison group (n = 6 per group) (Yoon et al., 2023).

With TEPP-46, 1 mM KY19382 sped closure further; at day 14, wounds given either agent alone still had scabs (Kim et al., 2023). An independent Nanjing group reported smaller wound areas, more collagen and more VEGFA and CD31 staining in streptozotocin-diabetic C57BL/6 mice given KY19382 at splinted wounds. Its cell work used 0.1 mM, at which fibroblast and endothelial cell growth fell by 72 hours (Chen et al., 2025). Models: human skin cells and mice.

Growth plate and bone length in young mice

Male C57BL/6 mice given 0.1 mg/kg KY19382 intraperitoneally each day for 2 weeks, from 3 or 7 weeks of age, had taller growth plates, more proliferating chondrocytes and more nuclear β-catenin. Daily exposure from 3 to 13 weeks of age lengthened the tibia compared with vehicle, with no histological abnormalities reported in articular cartilage or liver and no body weight difference (Choi et al., 2019). Model: male mice.

Cancer cell and skin tumor models

Given the role of Wnt signaling in cancer, the developers tested KY19382 in cutaneous squamous cell carcinoma (cSCC). In HSC-1 and HSC-5 human cSCC cells, 5 µM reduced proliferation, migration, invasion and colony formation, lowered CDK1, and lowered rather than raised Wnt/β-catenin signaling. Applied at 2 mM before each tumor-promoter application for 24 weeks in DMBA/TPA-exposed male C57BL/6 mice, it reduced tumor number and size (n = 10 per group) (Lee et al., 2025).

Independent groups used it as a Wnt agonist tool: 1 µM restored proliferation of lung adenocarcinoma cells after DYNLL1 knockdown (Li et al., 2025), and it reversed the loss of EMT and proliferation after STMN2 silencing in pancreatic cancer cells (Shao et al., 2023). Models: human cancer cells and mice.

Formulation for skin delivery

KY19382 is poorly soluble in water. Premixed 1:1 with hydroxypropyl-β-cyclodextrin, it dissolved at about 5 mg/mL in polyoxyl castor oil and polysorbate 80, and 3.1 mg/mL in PEG 400. A micellar mix of these three raised permeation through an artificial skin membrane compared with DMSO and stayed free of precipitate for 3 months at 4 and 25°C (Seo et al., 2020). Model: in vitro formulation tests.

Key studies

  1. Choi S, et al. "CXXC5 mediates growth plate senescence and is a target for enhancement of longitudinal bone growth." Life Sci Alliance. 2019. PMID 30971423. DOI 10.26508/lsa.201800254. Design paper: cell-free assays, ATDC5 cells and mice.
  2. Ryu YC, et al. "KY19382, a novel activator of Wnt/β-catenin signalling, promotes hair regrowth and hair follicle neogenesis." Br J Pharmacol. 2021. PMID 33751552. DOI 10.1111/bph.15438. Human dermal papilla cells, cultured follicles and C57BL/6N mice.
  3. Ryu YC, et al. "Wnt/β-catenin signaling activator restores hair regeneration suppressed by diabetes mellitus." BMB Rep. 2022. PMID 36016500. DOI 10.5483/BMBRep.2022.55.11.081. Diabetic mice and human follicles in high glucose.
  4. Yoon M, et al. "KY19382 Accelerates Cutaneous Wound ... via Activation of the Wnt/β-Catenin Signaling Pathway." Title shortened. Int J Mol Sci. 2023. PMID 37511501. DOI 10.3390/ijms241411742. Human skin cells and mouse wounds.
  5. Chen Y, et al. "CXXC5 function blockade promotes diabetic wound ... through stimulating fibroblast and vascular endothelial cell activation." Title shortened. Cell Commun Signal. 2025. PMID 40001144. DOI 10.1186/s12964-025-02097-z. Diabetic mice and human cells; independent group.
  6. Lee SH, et al. "Novel small molecules downregulate CDK1 expression and inhibit Wnt/β-catenin signaling in cutaneous squamous cell carcinoma by targeting its distinct tumor-specific cellular landscape." Exp Mol Med. 2025. PMID 40887499. DOI 10.1038/s12276-025-01532-y. Human cSCC cells and a mouse tumor model.

Handling and storage of KY19382 solution

General laboratory practice for this material:

  • Store the bottle at 15 to 25°C with the cap closed, away from direct light and heat, and do not freeze (storage guidance on the product page).
  • KY19382 is poorly water-soluble; in single-excipient solutions such as PEG 400 it tended to precipitate during storage, most clearly at 4°C (Seo et al., 2020). Check for haze or crystals before sampling and after aqueous dilution.
  • At 5MG/ML and 360.2 g/mol, the labeled solution is about 13.9 mM. Most published cell work used 0.01 to 5 µM.
  • Record the lot number and keep its certificate; where it reports measured content, use that rather than the label figure. For identity checks, compare analytical data with C₁₇H₁₁Cl₂N₃O₂ and 360.2 g/mol.

Frequently asked questions

Is KY-19382 the same compound as KY19382?

Yes. KY-19382 and KY 19382 are spellings of the same developer code; the papers write KY19382, and PubChem lists KY19382 and KY 19382 on CID 148959784.

How does KY19382 act on Wnt signaling?

Its developers report two actions that raise β-catenin: it blocks CXXC5 from binding Dishevelled, and it inhibits GSK-3β (Choi et al., 2019). In two cSCC cell lines it lowered Wnt signaling instead, alongside reduced CDK1 (Lee et al., 2025).

What has KY19382 done in hair follicle studies?

Studies measured mouse and tissue-culture endpoints only: anagen entry, follicle number, regrown hair weight and wound-induced neogenesis in mice, follicle length in culture, and alkaline phosphatase and β-catenin in dermal papilla cells (Ryu et al., 2021).

Has KY19382 been tested in people?

None of the 11 PubMed records that name KY19382 (searched 10 October 2026) reports giving it to people; their human material is cultured hair follicles, cultured cells and tumor tissue samples. Drugs@FDA lists no product under the name. It is not named on WADA's 2026 Prohibited List, whose S0 class covers pharmacological substances not addressed by any later section and with "no current approval by any governmental regulatory health authority for human therapeutic use."

How should KY19382 solution be stored?

Keep the bottle at 15 to 25°C with the cap closed, away from direct light and heat, and do not freeze, as listed on the product page.

Where can researchers buy KY19382?

Disguised Alpha sells it for laboratory research as a liquid research solution, 5MG/ML in a 30ML bottle (150MG total), with certificate access for each lot: KY-19382 (Wnt/β-Catenin Follicle Pathway).

Related compounds and guides

This product is for research use only. It has not been evaluated for safety or effectiveness in humans. Not for human consumption. All products are intended for laboratory research purposes only.

Certificates of analysis

Each tested batch of KY-19382 (Wnt/β-Catenin Follicle Pathway) has its own certificate page with the full lab results.

25% offGLPs15% off automaticallyUse code GLP or any code for 25% off0days00hrs00min00secShop the sale  →Shop